Trial
NCT02245737
An Efficacy and Safety Study of Lanabecestat (LY3314814) in Early Alzheimer's Disease
Phase IITERMINATEDEFFICACY/FUTILITYConfidence: HIGH
Sponsor
AstraZeneca
Collaborators
Eli Lilly and Company
Condition
Alzheimer´s Disease
Intervention
Lanabecestat
Why stopped
An independent assessment concluded the trial was not likely to meet the primary endpoint upon completion and therefore, trial stopped for futility
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2019-12-03